W
Weng-Yi Huang
Publications - 31
Citations - 116
Weng-Yi Huang is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 18 citations.
Papers
More filters
Journal ArticleDOI
Risk factors and subtype analysis of acute ischemic stroke.
TL;DR: The incidence of lacunar infarction was significantly higher in initial rather than recurrent stroke patients, and diabetes mellitus or hyperlipidemia was highly associated with Lacunar Infarction.
Journal ArticleDOI
The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
Emily Vogtmann,Xing Hua,Guoqin Yu,Vaishnavi Purandare,Autumn G Hullings,Dantong Shao,Yunhu Wan,Shi Lin Li,Casey L. Dagnall,Kristine Jones,Belynda Hicks,Amy Hutchinson,J. Gregory Caporaso,William Wheeler,Dale P. Sandler,Laura E. Beane Freeman,Linda M. Liao,Weng-Yi Huang,Neal D. Freedman,Neil E. Caporaso,Rashmi Sinha,Mitchell H. Gail,Jianxin Shi,Christian C. Abnet +23 more
TL;DR: Multiple oral microbial measures were prospectively associated with lung cancer risk in three US cohort studies with associations varying by smoking history and histologic subtype, suggesting the oral microbiome may offer new opportunities for lung cancer prevention.
Journal ArticleDOI
Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia
Eleanor L. Watts,Aurora Perez-Cornago,Georgina K. Fensom,Karl Smith-Byrne,Urwah Noor,Colm Andrews,Marc J. Gunter,Michael C. Holmes,Richard J. Martin,Konstantinos K. Tsilidis,Demetrius Albanes,Aurelio Barricarte,H. Bas Bueno-de-Mesquita,Chu Chen,Barbara A. Cohn,Niki Dimou,Luigi Ferrucci,Leon Flicker,Neal D. Freedman,Graham G. Giles,Edward Giovannucci,Gary E. Goodman,Christopher A. Haiman,Graeme J. Hankey,Jiaqi Huang,Weng-Yi Huang,Lauren M. Hurwitz,Rudolf Kaaks,Paul Knekt,Tatsuhiko Kubo,Hilde Langseth,Gail A. Laughlin,Loic Le Marchand,Tapio Luostarinen,Robert J. MacInnis,Hanna Mäenpää,Satu Männistö,E. Jeffrey Metter,Kazuya Mikami,Lorelei A. Mucci,Anja Olsen,Kotaro Ozasa,Domenico Palli,Kathryn L. Penney,Elizabeth A. Platz,Harri Rissanen,Norie Sawada,Jeannette M. Schenk,Pär Stattin,Akiko Tamakoshi,Elin Thysell,C. Jillian Tsai,Shoichiro Tsugane,L V Vatten,Elisabete Weiderpass,Stephanie J. Weinstein,Lynne R. Wilkens,Bu B. Yeap,Naomi E. Allen,Timothy J. Key,Ruth C. Travis +60 more
TL;DR: The results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups, with null associations in MR analysis.
Journal ArticleDOI
Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures
Peter Georgeson,Tabitha A. Harrison,Bernard J. Pope,Syed H.E. Zaidi,Conghui Qu,Robert S. Steinfelder,Yi-Kuei Lin,Jihoon E. Joo,Khalid Mahmood,Mark Clendenning,Romy Walker,Efrat L. Amitay,Sonja I. Berndt,Hermann Brenner,Peter J. Campbell,Yin Cao,Andrew T. Chan,Jenny Chang-Claude,Kimberly F. Doheny,David A. Drew,Jane C. Figueiredo,Amy J. French,Steven Gallinger,Marios Giannakis,Graham G. Giles,Andrea Gsur,Marc J. Gunter,Michael Hoffmeister,Li Hsu,Weng-Yi Huang,Paul J. Limburg,JoAnn E. Manson,Victor Moreno,Rami Nassir,Jonathan A. Nowak,Mireia Obón-Santacana,Shuji Ogino,Amanda I. Phipps,John D. Potter,Robert E. Schoen,Wei Sun,Amanda E. Toland,Quang M. Trinh,Tomotaka Ugai,Finlay A. Macrae,Christophe Rosty,Thomas J. Hudson,Mark A. Jenkins,Stephen N. Thibodeau,Ingrid Winship,Ulrike Peters,C. D. Buchanan +51 more
TL;DR: In this article , the discriminatory potential of a tumor mutational signature specific to MUTYH for identifying biallelic carriers and classifying variants of uncertain clinical significance (VUS) was evaluated.
Posted ContentDOI
Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program
Hilary A. Robbins,Karine Alcala,Elham Khodayari Moez,Florence Guida,Sera-Melisa Thomas,H.A. Zahed,M Warkentin,Karl Smith-Byrne,Yonathan Brhane,David Miller,Xiaoshuang Feng,Demetrius Albanes,Melinda C. Aldrich,Alan A. Arslan,Julie K. Bassett,Christine D. Berg,Qiuyin Cai,Chu Chen,Michael P.A. Davies,Brenda Diergaarde,John K. Field,Neal D. Freedman,Weng-Yi Huang,Mikael Johansson,Michael Jones,Woon-Puay Koh,Stephen Lam,Qing Lan,Arnulf Langhammer,Linda M. Liao,Geoff Liu,Reza Malekzadeh,Roger L. Milne,Luis M. Montuenga,Thomas E. Rohan,Howard D. Sesso,Gianluca Severi,Mahdi Sheikh,Rashmi Sinha,Xiao-Ou Shu,Victoria L. Stevens,Martin C. Tammemägi,Lesley F. Tinker,Kala Visvanathan,Ying Wang,Renwei Wang,Stephanie J. Weinstein,Emily White,D. Wilson,Jian-Min Yuan,Xuehong Zhang,Wei Zheng,Christopher I. Amos,Paul Brennan,Mattias Johansson,Rayjean J. Hung +55 more
TL;DR: The rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL are described and future progress to advance lung cancer early detection biomarkers will require carefully designed validation, translational, and comparative studies.